Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trading Halts

Cara Therapeutics (CARA) FV Target Raised to $33 at JanneyMay 29, 2019 3:40 PM Cara Therapeutics (CARA) PT Raised to $33 at JefferiesMay 29, 2019 11:20 AM Cara Therapeutics (CARA) PT Raised to $28 at H.C. WainwrightMay 29, 2019 10:55 AM Stifel Reiterates Buy Rating on Cara Therapeutics (CARA)May 29, 2019 8:23 AM Cara Therapeutics (CARA) to Resume Trading at 7:30 am ETMay 29, 2019 7:04 AM Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with PruritusMay 29, 2019 7:01 AM Cara Therapeutics (CARA) Halted, News PendingMay 29, 2019 6:55 AM